DPPE-PEG350
Based on 1 Customer Validation
DPPE-PEG350 (16:0 PEG350 PE) is a CD1d lipid antagonist. DPPE-PEG350 blocks alpha-GalCer-dependent ERK tyrosine kinase phosphorylation in cells. DPPE-PEG350 inhibits cellular IL-4 and IFN-gamma production following alpha-GalCer stimulation. DPPE-PEG350 selectively antagonizes iNKT without affecting MHC class II-dependent OVA-specific Th2 responses. DPPE-PEG350 reduces MCP-1 and VCAM-1 protein expression and necrotic core formation in atherosclerotic lesions. DPPE-PEG350 can be used for research on asthma and atherosclerosis.
For research use only. We do not sell to patients.
- Purity : 99%
- CAS No.: 474922-84-4
- Formula: (C2H4O)nC39H76NO10P.H3N
- Molecular Weight:350(Average)
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
IC50 & Target
[1]|
CD1d |
IL-4 |
In Vitro
DPPE-PEG350 (200 µg/mL; 4 h) inhibits α-GalCer-dependent IL-2 release from DN32.D3 cells, particularly at suboptimal α-GalCer concentrations[1].
DPPE-PEG350 (50 µg/mL) inhibits CD1d-dependent activation of iNKT by ILC2 in co-culture, while iNKT dampen IL-5 release from ILC2[4].
DPPE-PEG350 (0-100 µg/mL; 4 h) competes with α-GalCer for binding to CD1d on DN32 iNKT cell hybridomas in a dose-dependent manner[1].
DPPE-PEG350 is a chemical lipid antagonist that blocks NKT cell activation by competing with lipid antigens in CD1d binding[3].
DPPE-PEG350 (5 µg/mL) significantly inhibits the formation of CD1d-α-GalCer complexes, confirming its role as a CD1d antagonist[1].
DPPE-PEG350 (12.5-100 µg/mL; 1-60 min) completely blocks α-GalCer-induced ERK phosphorylation in iNKT cells at 100 µg/mL, thereby inhibiting TCR signaling[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:DN32.D3 NKT hybridoma cells
-
Concentration:200 µg/mL
-
Incubation Time:4 h
-
Result:Inhibited IL-2 release from DN32 cells, particularly at suboptimal concentrations of α-GalCer.
In Vivo
DPPE-PEG350 (100 µg; intranasal administration; single dose) completely prevents α-GalCer-induced AHR and lung inflammation in naive mice[1].
DPPE-PEG350 (250 µg; intravenous injection; twice weekly) reduces atherosclerotic progression by 45% in mice without affecting plasma lipids or lymphocyte populations, primarily by reducing lesional T cells, B cells, MCP-1, VCAM-1, and necrotic core content[2].
DPPE-PEG350 (500 µg; intravenous injection; once weekly) completely eliminates αGalCer-aggravated atherosclerosis in mice, confirming the CD1d-dependent anti-atherosclerotic effect[2].
DPPE-PEG350 (250 µg; intravenous injection; twice weekly; 6 weeks) slows the progression of established atherosclerosis by 49%, reduces the necrotic core by 59%, and decreases lesional immune cell content in mice without affecting smooth muscle or collagen[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/cByj (female, 6-8 weeks old, OVA-induced allergic airway hyperreactivity)[1]
-
Dosage:250 µg
-
Administration:i.v.; single dose
-
Result:Completely prevented the development of airway hyperreactivity upon intranasal OVA challenge.
Inhibited eosinophilic airway inflammation, significantly reducing the number of eosinophils, lymphocytes, and macrophages in the BAL fluid compared to the OVA-immunized control group.
Revealed no significant differences from saline controls in H&E- and PAS-stained lung sections, showing minimal mucus production and negligible cellular infiltration.
-
Animal Model:BALB/cByj (female, 6-8 weeks old, α-GalCer-induced airway hyperreactivity)[1]
-
Dosage:100 µg
-
Administration:i.n.; single dose
-
Result:Completely prevented the development of AHR in the group that received DPPE-PEG350 and α-GalCer when compared with α-GalCer alone.
Administration of DPPE-PEG350 alone showed no effect on the induction of AHR or pulmonary inflammation.
Revealed no significant differences between vehicle control and DPPE-PEG350-treated mice in H&E- and PAS-stained lung sections, showing minimal mucus production and minor cellular infiltration.
-
Animal Model:ApoE-/- mice on C57BL/6 background (male, 6-8 weeks old)[2]
-
Dosage:250 µg
-
Administration:i.v.; twice weekly
-
Result:Reduced total intimal atherosclerotic lesion size by 45% and ORO-stained lipid accumulation by 52% compared to PBS group.
Reduced CD4+ T cells by 54%, CD8+ T cells by 94%, and CD19+ B cell accumulation by 80% in atherosclerotic lesions.
Reduced MCP-1 and VCAM-1 protein expression by 30% and 57% respectively.
Reduced necrotic core areas by 64%.
Did not affect liver NKT cell populations (NK1.1+TCRβ+), CD4+ T cells, CD8+ T cells, B cells, or NK cells.
Did not affect plasma lipids despite ~10% reduction of body weight.
Did not affect smooth muscle and collagen content in atherosclerotic lesions.
Did not affect IFNγ mRNA expression in arterial and spleen tissues or plasma IFNγ levels.
-
Animal Model:ApoE-/- mice on C57BL/6 background (male, 6-8 weeks old)[2]
-
Dosage:250 µg
-
Administration:i.v.; twice weekly; 6 weeks
-
Result:Reduced established atherosclerosis by 49% when assessed by total intimal lesion areas.
Reduced lipid accumulation in aortic sinus lesions by 27%.
Reduced necrotic cores by 59%.
Reduced CD68+ macrophages, CD4+ T cells, CD8+ T cells, and CD19+ B cells in atherosclerotic lesions.
Decreased apoptotic cells in developed atherosclerotic lesions, with macrophages being a major target of apoptosis.
Did not affect the ratio of lipid accumulation to intima area.
Did not affect smooth muscle and collagen content in established atherosclerotic lesions.
Did not affect endothelial cell continuity.
-
Animal Model:ApoE-/- mice on C57BL/6 background (male, 6-8 weeks old)[2]
-
Dosage:500 µg (DPPE-PEG350); 2 µg (αGalCer)
-
Administration:i.v.; once weekly (DPPE-PEG350); i.p.; fortnightly (αGalCer)
-
Result:Completely abrogated αGalCer-aggravated atherosclerosis, which increased total intimal lesion by 112% without DPPE-PEG350 treatment.
Similar finding was observed with ORO-stained lipid accumulation; however lipid contents adjusted to lesion area were similar.
FACS analysis of liver lymphocytes showed that αGalCer-injection reduced CD1d-tetramer+ iNKT cells.
Chemical Information
-
CAS No. 474922-84-4
-
Appearance Solid
-
Molecular Weight 350(Average)
-
Formula (C2H4O)nC39H76NO10P.H3N
-
Color White to light yellow
-
SMILES
O=C(NCCOP(O)(OC[C@@H](COC(CCCCCCCCCCCCCCC)=O)OC(CCCCCCCCCCCCCCC)=O)=O)OCCOC.N.[n]
-
Synonyms
16:0 PEG350 PE; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-350] ammonium
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Naïve CD4+ T-cell subset differentiation/polarization
Naïve CD4+ T-cell subset differentiation/polarization is an in vitro assay in which purified naïve CD4+ T cells are activated through TCR and CD28 costimulation and cultured with defined cytokines and neutralizing antibodies to generate Th0, Th1, Th2, Th17, or induced Treg-like populations. Differentiation is detected by subset-associated cytokines and transcription factors: IFN-γ/T-bet for Th1, IL-4/GATA3 for Th2, IL-17A/RORγt for Th17, and Foxp3 for induced Treg cells. The assay readout is usually generated by intracellular cytokine staining after restimulation, transcription-factor staining by flow cytometry, ELISA of secreted cytokines, or gene-expression analysis. The result reflects cytokine-directed lineage commitment or polarization rather than antigen-specific immune protection by itself.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Protocol For Protein Expression And Purification
Recombinant protein expression in Escherichia coli followed by purification of a His-tagged soluble protein by immobilized metal affinity chromatography (IMAC), with optional MBP fusion and TEV tag removal when the construct includes these elements. The biological readout is production of the encoded target protein, detected as an inducible band at the expected molecular mass by SDS-PAGE and quantified by total protein assay or chromatographic absorbance; the purification readout is enrichment of the target protein in elution fractions after selective binding of polyhistidine residues to immobilized Ni2+/metal-chelate resin and elution by imidazole-containing buffer. Expression is driven by an inducible bacterial expression system, commonly T7/lac-based, in which IPTG or lactose/auto-induction activates transcription and translation of the cloned gene; lower induction temperature, lower inducer concentration, induction timing, and solubility-enhancing fusion tags can influence the frac
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[1]. Lombardi V, et al. A CD1d-dependent antagonist inhibits the activation of invariant NKT cells and prevents development of allergen-induced airway hyperreactivity. Journal of immunology (Baltimore, Md. : 1950). 2010 Feb 15;184(4):2107-15. [Content Brief]
[2]. Li Y, et al. A CD1d-dependent lipid antagonist to NKT cells ameliorates atherosclerosis in ApoE-/- mice by reducing lesion necrosis and inflammation. Cardiovasc Res. 2016 Feb 1;109(2):305-17. . [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- DPPE-PEG350
- 474922-84-4
- 16:0 PEG350 PE
- 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-350]
- CD1
- ERK
- Interleukin Related
- IFNAR
- asthma
- CD1d lipid antagonist
- ApoE-/- mice
- IFN-gamma
- alpha-GalCer
- iNKT cell activation
- IL-4
- atherosclerosis
- invariant TCR signaling
- ERK tyrosine kinase phosphorylation
- Inhibitor
- inhibitor
- inhibit